Ra. Byrne et al., E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup, J UROL, 165(5), 2001, pp. 1473-1479
Purpose: We analyze the expression of E-cadherin in bladder transitional ce
ll carcinoma, areas of carcinoma in situ and lymph node metastases, and det
ermine the value of E-cadherin immunoreactivity for predicting disease prog
ression and survival of patients with bladder transitional cell carcinoma.
Materials and Methods: The study group consisted of 77 patients who underwe
nt radical cystectomy. Formalin fixed paraffin sections were processed with
a hot, citric acid antigen retrieval method, followed by immunostaining wi
th anti-E-cadherin monoclonal antibody and a standard avidin biotin complex
technique. E-cadherin expression was also evaluated in carcinoma in situ s
ections (18) and in regional lymph node metastases (17).
Results: Loss of normal membrane E-cadherin immunoreactivity was found in 5
9 (77%) patients. Abnormal expression of E-cadherin was associated with mus
cle invasive disease (p = 0.010) and lymph node metastasis (p = 0.044). Of
the 18 carcinoma in situ specimens 15 (83%) and of the 17 metastatic lymph
nodes 13 (76%) had abnormal E-cadherin expression. Concordance rates of E-c
adherin status in carcinoma in situ areas and metastatic lymph nodes with t
he primary tumors were 85% and 88%, respectively. At a median followup of 1
28 months, abnormal E-cadherin expression was significantly associated with
disease progression (p = 0.0219) and bladder cancer specific survival (p =
0.037). E-cadherin expression and pathological stage but not grade were in
dependent predictors of disease progression (p = 0.042, 0.047 and 0.158, re
spectively).
Conclusions: In bladder cancer alter ed E-cadherin expression is associated
with the degree of invasiveness, lymph node metastasis and increased risk
of death from bladder cancer. Furthermore, E-cadherin status is an independ
ent predictor of disease progression in patients treated with cystectomy fo
r transitional cell carcinoma of the bladder.